Q3 2025 Management View President and CEO Eric Dube emphasized "exceptional progress across our three key priorities: ...

We recently published 10 Firms Dominating the Market; 5 at All-Time Highs. Travere Therapeutics, Inc. (NASDAQ:TVTX) is one of ...

Investing.com -- Travere Therapeutics, Inc. (NASDAQ:TVTX) reported third-quarter earnings that significantly exceeded analyst expectations, driven by robust sales growth of its kidney disease ...

Travere Therapeutics (TVTX) delivered a quarterly update that caught investors’ attention, as the company posted substantial revenue growth and turned a profit in Q3 2025. The results reflected strong ...

SAN DIEGO, September 10, 2025--(BUSINESS WIRE)--Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that following ...

Travere Therapeutics recently received accelerated approval for Filspari (sparsentan) for the treatment of IgA Nephropathy (IgAN) and raised $200 million in a public offering. The company may struggle ...

The U.S. Food and Drug Administration (FDA) granted accelerated approval to Travere Therapeutics' (NASDAQ:TVTX) oral medicine Filspari (sparsentan) to reduce proteinuria in adults with primary IgAN at ...

(RTTNews) - Travere Therapeutics Inc. (TVTX) announced that new data further demonstrates the clinical benefit of FILSPARI (sparsentan) in IgA nephropathy (IgAN) and reinforces its potential in focal ...

(RTTNews) - Travere Therapeutics Inc. (TVTX) said that the U.S. Food and Drug Administration granted accelerated approval to Filspari (sparsentan) to reduce proteinuria in adults with primary IgA ...

Data from SPARTACUS and PROTECT OLE to show significant proteinuria reduction when replacing RASi with FILSPARI and when FILSPARI is used in combination with SGLT2i New mechanistic data to show ...

If approved, FILSPARI would be the first and only FDA-approved treatment for FSGS, a rare kidney condition and a leading cause of kidney failure SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. ...

The update now reduces the frequency of liver function monitoring to every 3 months from the onset of treatment. The Food and Drug Administration (FDA) has updated the risk evaluation and mitigation ...